Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 546

1.

Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings.

O'Connor PJ, Gray RJ, Maciosek MV, Fillbrandt KM, DeFor TA, Alexander CM, Weiss TW, Teutsch SM.

Prev Chronic Dis. 2005 Jul;2(3):A05. Epub 2005 Jun 15.

2.

Prevalence of dyslipidemia and lipid goal attainment in statin-treated subjects from 3 data sources: a retrospective analysis.

Jones PH, Nair R, Thakker KM.

J Am Heart Assoc. 2012 Dec;1(6):e001800. doi: 10.1161/JAHA.112.001800. Epub 2012 Dec 19.

3.

Cholesterol efflux and metabolic abnormalities associated with low high-density-lipoprotein-cholesterol and high triglycerides in statin-treated coronary men with low-density lipoprotein-cholesterol <70 mg/dl.

Posadas-Sánchez R, Posadas-Romero C, Mendoza-Pérez E, Caracas-Portilla NA, Cardoso-Saldaña G, Medina-Urrutia A, Jorge-Galarza E, Juárez-Rojas JG.

Am J Cardiol. 2012 Mar 1;109(5):636-41. doi: 10.1016/j.amjcard.2011.10.017. Epub 2011 Dec 9.

PMID:
22169129
4.

Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol.

Alsheikh-Ali AA, Lin JL, Abourjaily P, Ahearn D, Kuvin JT, Karas RH.

Am J Cardiol. 2007 Nov 15;100(10):1499-501. Epub 2007 Sep 27.

PMID:
17996508
5.

Mixed dyslipidemias in primary care patients in France.

Laforest L, Ambegaonkar BM, Souchet T, Sazonov V, Van Ganse E.

Vasc Health Risk Manag. 2012;8:247-54. doi: 10.2147/VHRM.S27668. Epub 2012 Apr 19.

6.

HMG-CoA reductase inhibitor (Statin) therapy and coronary atherosclerosis in Japanese subjects: role of high-density lipoprotein cholesterol.

Tani S, Nagao K, Hirayama A.

Am J Cardiovasc Drugs. 2011 Dec 1;11(6):411-7. doi: 10.2165/11594620-000000000-00000.

PMID:
22149320
8.

[Magnitude and characteristics of residual lipid risk in patients with a history of coronary revascularization: the ICP-bypass study].

González-Juanatey JR, Cordero A, Vitale GC, González-Timón B, Mazón P, Bertomeu V.

Rev Esp Cardiol. 2011 Oct;64(10):862-8. doi: 10.1016/j.recesp.2011.05.022. Epub 2011 Aug 10. Spanish.

10.
11.
12.

Lipid management in 13,000 high risk cardiovascular patients treated under daily practice conditions: LIMA Registry.

Schaefer JR, Gitt AK, Sonntag F, Weizel A, Jannowitz C, Karmann B, Pittrow D, Bestehorn K.

Vasc Health Risk Manag. 2013;9:71-80. doi: 10.2147/VHRM.S37143. Epub 2013 Feb 21.

13.
14.

Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment.

Kastelein JJ, van der Steeg WA, Holme I, Gaffney M, Cater NB, Barter P, Deedwania P, Olsson AG, Boekholdt SM, Demicco DA, Szarek M, LaRosa JC, Pedersen TR, Grundy SM; TNT Study Group; IDEAL Study Group.

Circulation. 2008 Jun 10;117(23):3002-9. doi: 10.1161/CIRCULATIONAHA.107.713438. Epub 2008 Jun 2.

15.

Hypercholesterolemia treatment patterns and low-density lipoprotein cholesterol monitoring in patients with a diagnosis of atherosclerosis in clinical practice.

Davidson MH, Gandhi SK, Ohsfeldt RL, Fox KM.

Am J Med. 2009 Jan;122(1 Suppl):S51-9. doi: 10.1016/j.amjmed.2008.10.017.

PMID:
19110088
16.

Usefulness of statin-ezetimibe combination to reduce the care gap in dyslipidemia management in patients with a high risk of atherosclerotic disease.

Teoh H, Mendelsohn AA, Goodman SG, Jaffer S, Chen RY, Tjia S, Theriault L, Langer A, Leiter LA; Guidelines Based Undertaking for Improvement in Dyslipidemia Related Events (GUIDE) Investigators.

Am J Cardiol. 2009 Sep 15;104(6):798-804. doi: 10.1016/j.amjcard.2009.05.019. Epub 2009 Jul 23.

PMID:
19733714
17.

Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis.

Nicholls SJ, Tuzcu EM, Sipahi I, Grasso AW, Schoenhagen P, Hu T, Wolski K, Crowe T, Desai MY, Hazen SL, Kapadia SR, Nissen SE.

JAMA. 2007 Feb 7;297(5):499-508.

PMID:
17284700
20.

Frequency of obtaining national cholesterol education program adult treatment panel III goals for all major serum lipoproteins after initiation of lipid altering therapy.

Nichols GA, Ambegaonkar BM, Sazonov V, Brown JB.

Am J Cardiol. 2009 Dec 15;104(12):1689-94. doi: 10.1016/j.amjcard.2009.07.050.

PMID:
19962476
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk